Payer Contract Reimbursement Rate Benchmarks for Infusion Centers

A payer rate benchmark is not one kind of number. Infusion centers that treat every figure labeled "benchmark" as interchangeable make negotiation mistakes and miss underpayments because of how they read the data. Three separate things get called a benchmark in infusion reimbursement, and each one answers a different question.

CMS publishes these rates, fixes them, and updates them once a year. Commercial contracted rates are negotiated privately between a practice and a payer, and they stay confidential, varying by payer and by the specific terms of each contract. Market comparison data is aggregated, anonymized, and reported by other providers, useful for seeing where a practice stands relative to peers but not built for checking whether a specific claim paid correctly.

Medicare rates tell a practice what the regulatory floor looks like. Commercial rates tell a practice what one particular payer has agreed to pay, under one particular contract. Market data tells a practice whether its negotiated rate sits above or below what comparable practices have secured elsewhere. None of the three can do the other two jobs.

The two most common misapplications both come from collapsing this distinction. One is treating Medicare rates as a stand-in for commercial adequacy, as if paying more than Medicare automatically means paying enough. The other is treating market aggregates as a substitute for checking actual contract performance claim by claim. Both habits lead to the same outcome: underpayments that go unnoticed because the number on the page looked reasonable.

Medicare's Administrative Floor for Home Infusion Therapy

Medicare home infusion therapy rates come from a formula set in statute, not from negotiation. That is why they work as a stable reference point, and also why they fall short as a commercial target. Under CMS Change Request 14308, effective January 1, 2026, the payment amount rises each year by the CPI-U measured over the 12 months ending in June, reduced by the 10-year moving average of economy-wide private non-farm business Multifactor Productivity. For CY 2026, that calculation produced an inflation-less-productivity factor of 2.0%, applied along with a GAF standardization factor.

The resulting national unadjusted rates are public and specific. G0068, the code for administering an IV anti-infective, pain management, chelation, pulmonary hypertension, or inotropic drug on a subsequent visit, pays $190.22. G0090 covers an initial visit with IV chemotherapy or another highly complex biologic, and it pays $388.89. Chemotherapy administration demands more nursing time and drug complexity than a routine anti-infective visit does, and that is why the two figures differ.

These national figures are a starting point, not a finish line. If a practice is in a high-cost urban market, the geographic wage index adjusts its rate away from the national unadjusted figure. That is why quoting the national rate alone is not enough for local contract comparison.

The statute also sets a ceiling: the single payment amount for home infusion therapy cannot exceed what the Medicare Physician Fee Schedule would pay for the same service delivered in a physician's office. So physician-office and clinic-based infusion practices get their own cross-reference point when they evaluate rates.

One more structural fact matters here. HCPCS S9330 and its related codes, S9329 and S9331, make up the S-code system, and commercial and Medicaid channels use it exclusively. Traditional Medicare does not use these codes. Many commercial payers rely on S-codes as the primary coding layer for home infusion chemotherapy, and because these are temporary national codes, their rates are negotiated case by case and published nowhere.

Medicare Rates as a Commercial Benchmark

Medicare sets the floor, but commercial payers build their reimbursement on entirely different methodologies, so a contract that pays more than Medicare can still underpay in practice. But knowing where the floor sits tells a practice nothing about whether its commercial contracts actually cover cost.

AmerisourceBergen's white paper on home infusion reimbursement makes this divergence explicit: commercial and managed care payers, including managed Medicare and managed Medicaid plans, use a wide range of reimbursement methods for drugs, infusion pumps, supplies, and skilled nursing services. None of these methods tie back to the G-code HIT rate structure that Medicare uses. A commercial payer might reimburse the drug component as a percentage of billed charges, as a markup over Average Wholesale Price, or as a discount off Average Sales Price. Each of those three approaches produces a different net recovery on the identical drug at the identical dose.

Medicare Advantage plans deserve particular scrutiny. They have to cover home infusion therapy, but they set their own internal rate structures, and those structures may or may not track traditional Medicare's HIT rates. The AmerisourceBergen white paper also notes that traditional Medicare's home infusion coverage still lags behind other payers in breadth, which gives Medicare Advantage plans more room to vary in how they handle these services and makes their behavior harder to predict from the traditional Medicare rate alone.

The practical result: two contracts can both pay above Medicare and still land in very different places financially. A biologic infusion reimbursed at ASP plus a markup produces one margin. The same infusion reimbursed as a percentage of billed charges, where the billed-charges schedule itself has been set artificially low, produces a much thinner one, even though both contracts would appear "above Medicare" on a simple comparison.

Drug Category, Therapy Type, and Commercial Rate Variation

The widest swings in commercial reimbursement do not come from where care is delivered. They come from what kind of drug and what kind of therapy is being administered. Biologics, chemotherapy, anti-infectives, and subcutaneous therapies each get treated differently by payers. A single contracted "infusion rate" cannot describe what a practice will actually collect across its full drug portfolio.

Medicare's own rate table shows this logic directly. G0070 and G0090, covering chemotherapy and other highly complex biologics, pay materially more than G0068 and G0088, which cover anti-infective and pain management infusions. That gap exists because chemotherapy administration demands more nursing time, and it involves higher drug cost. Commercial contracts that fail to build in a similar tiered structure compress margins specifically on the highest-cost therapies, the ones where the compression hurts most.

Buy-and-bill biologics carry the highest stakes in this category breakdown. The practice has already purchased the drug before filing the claim, so a reimbursement rate that falls short of acquisition cost plus administration cost does not just shrink revenue. It turns that infused encounter into an outright operating loss.

Subcutaneous immunotherapy occupies its own tier for a reason. On the Medicare side, G0069 and G0089 reflect administration time and nursing requirements that differ from standard IV infusion. Commercial contracts that lump every non-chemotherapy infusion into one flat rate category are, structurally, underpaying this specific service type every time it occurs.

The S-code system used by many commercial payers for chemotherapy infusion adds a further layer of risk. S9329 covers standard infusion, S9330 covers continuous infusion, and S9331 covers intermittent infusion, each under a per-diem payment model, in contrast to Medicare's per-15-minute model. Depending on how long an infusion actually runs, the per-diem model can produce a very different net recovery than the time-based model would. When a contract does not specify which model applies to which scenario, that ambiguity tends to get resolved in the payer's favor.

What contract structure variables produce rate variation that benchmarks alone cannot reveal

Two contracts can advertise the same headline rate and still produce very different collections once the fine print is applied. Four structural variables drive that gap: the reimbursement basis, the unit definition, how add-on administration codes get handled, and how the contract treats biosimilar substitution.

Reimbursement basis determines how strong a given rate really is. A percent-of-billed-charges contract only pays well if the practice's chargemaster stays current. If billed charges have not been updated to reflect today's drug acquisition costs, even a high percentage applied to a stale number produces an inadequate dollar recovery. An ASP-based contract carries a parallel risk: it is only as strong as how often the practice updates its ASP figures.

Unit definition changes the payout for the same clinical encounter. Per-diem contracts pay once for the infusion day, no matter how long the infusion runs. Medicare uses per-15-minute contracts for HIT services, and these scale payment with nursing time. Medicare might reimburse a long biologic infusion across several 15-minute units, but a commercial per-diem contract might pay one flat rate for it, no matter how many hours it actually took. That structure suppresses recovery specifically on the therapies that demand the most nursing time.

Add-on code treatment is easy to miss because a simple rate comparison rarely includes it. Codes for sequential infusions, concurrent infusions, and prolonged service are often bundled into the primary rate or excluded from the contract by default. A benchmark check that only looks at the primary infusion code will miss the revenue lost to add-ons that the contract quietly excludes.

Biosimilar and new-drug handling rounds out the list. Contracts silent on how J-codes or HCPCS codes get updated leave real ambiguity about how a newly introduced biosimilar gets reimbursed. The AmerisourceBergen white paper notes that payers differ in which codes they accept depending on the type of billing entity submitting the claim, which adds another layer of inconsistency on top of an already uneven system.

Constructing a Working Benchmark for Payer Mix and Drug Portfolio

A benchmark only works if you build it around a specific practice's actual drug mix and payer contracts, coded line by line. A single average reimbursement figure cannot support contract negotiation or catch underpayments, because it hides the variation the earlier sections describe.

Start by establishing the Medicare floor code by code. Use the locality-adjusted HIT rates for the practice's actual geography, not the national unadjusted figures. The locality-adjusted number reflects what Medicare actually pays in that specific market, which makes it the correct floor for comparison, while the national figure only describes an average that no single practice collects.

Next, you map the practice's real therapy and drug mix onto HCPCS codes. A practice running mostly high-complexity biologic infusions needs a benchmark profile built around G0070 and G0090-type rates. A practice running mostly anti-infective therapy needs one built around G0068 and G0088. The benchmark has to weight each code by volume and by drug cost, since treating every code as equally important hides where the real financial exposure sits.

Then calculate expected reimbursement payer by payer, code by code. For each commercial contract, apply its stated reimbursement basis, whether that is a percentage of billed charges, an ASP-based markup, or an AWP discount, to a representative claim for each relevant code. Compare that dollar figure against the Medicare floor and against whatever market data you can get from aggregated sources. That comparison, run at the code level rather than as a single blended average, is what actually shows a practice where a contract underperforms.

If a practice tracks payer performance against contracted rates this way, instead of relying on one aggregate collection ratio, it can catch flat underpayments and payer-specific patterns before they turn into permanent write-offs. Because infusion billing requires tracking drug cost, J-code units, administration time, and authorization status all at once, a general billing system tends to absorb discrepancies into one broad contractual-adjustment line, obscuring them there. A platform built specifically for infusion revenue cycle work, reconciling at the payer level and the code level, is positioned to catch that variance and flag it for review.

Where benchmark data should drive contract renegotiation versus where it should drive operational changes

Not every gap between what a practice expected and what it actually collected points to a bad contract. A meaningful share of those gaps come from coding errors, missed authorizations, or claims submission mistakes, and no amount of renegotiating will fix a problem that originates in billing execution.

Contract renegotiation is the right move when the benchmark work shows the contract's stated rate for a specific code or drug category falling demonstrably below market comparables for that same code and category. If the code-by-code comparison built in the previous section shows a payer paying below both the Medicare floor and available market data for chemotherapy infusion codes like G0070 or G0090, that gap lives in the contract terms themselves and has to be addressed at the negotiating table.

Operational repair is the right move when the gap traces back to how claims get coded and submitted. A practice billing per-diem when a per-15-minute model would have paid more, failing to bill add-on codes the contract actually allows, or submitting claims against outdated chargemaster figures will show an underpayment that looks identical to a bad contract on the surface. The fix for that kind of gap is in the billing workflow, not in the next round of contract talks.

So you need that same code-level, payer-level view the benchmarking method builds to separate these two causes. A rate gap that appears consistently across every claim for a given code, for a given payer, points to the contract. A rate gap that appears inconsistently, tied to specific claims or specific billing staff, points to execution. Reading benchmark data correctly means asking which of these two problems is in front of the practice before deciding what to do about it.